Outlook Therapeutics Inc
F:41O
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
Outlook Therapeutics Inc
F:41O
|
US |
|
F
|
F5 Inc
F:FFV
|
US |
|
MTU Aero Engines AG
XETRA:MTX
|
DE |
|
M
|
Marriott International Inc
F:MAQ
|
US |
Outlook Therapeutics Inc
Outlook Therapeutics is a biopharmaceutical company focused on eye diseases, especially retinal conditions that can threaten vision. Its main work is to develop and seek approval for an ophthalmic version of bevacizumab, a drug designed to be used in the eye rather than in its original cancer-treatment form. The company does not sell a broad range of medicines. Its business is centered on developing, testing, and commercializing one main product candidate for wet age-related macular degeneration and related retinal uses. If approved, it would sell the treatment to ophthalmologists, retina specialists, hospitals, and clinics that treat patients with these chronic eye conditions. Outlook Therapeutics makes money, when it has a product on the market, by selling prescription drug product and by working through the drug approval and launch process with regulators and healthcare providers. Its role in the industry is narrow but important: it is trying to turn an established active ingredient into a purpose-built eye treatment with a delivery format aimed at retinal care.
Outlook Therapeutics is a biopharmaceutical company focused on eye diseases, especially retinal conditions that can threaten vision. Its main work is to develop and seek approval for an ophthalmic version of bevacizumab, a drug designed to be used in the eye rather than in its original cancer-treatment form.
The company does not sell a broad range of medicines. Its business is centered on developing, testing, and commercializing one main product candidate for wet age-related macular degeneration and related retinal uses. If approved, it would sell the treatment to ophthalmologists, retina specialists, hospitals, and clinics that treat patients with these chronic eye conditions.
Outlook Therapeutics makes money, when it has a product on the market, by selling prescription drug product and by working through the drug approval and launch process with regulators and healthcare providers. Its role in the industry is narrow but important: it is trying to turn an established active ingredient into a purpose-built eye treatment with a delivery format aimed at retinal care.
FDA win: Outlook Therapeutics said it has become a commercial-stage company after FDA approval of LYTENAVA, its ophthalmic bevacizumab for wet AMD, which management called a transformational milestone.
Launch plan: The company expects to launch in the U.S. later this year, with commercialization focused on payer access, reimbursement setup, supply readiness, and a targeted retina-specialist sales force.
Sales outlook: Management reiterated a base case of more than $500 million in peak annual U.S. sales by 2030, while saying a disruption in compounded bevacizumab could add just under $300 million of upside.
Pricing: LYTENAVA’s WAC is expected to be below $500 per vial, which management said is intended to stay competitive with biosimilars and other anti-VEGF therapies.
Funding: The company ended the quarter with $11.2 million in cash and announced a $55 million stock-and-warrants offering, expected to bring in about $51.1 million in net proceeds.
Europe: European revenue is improving, with unit sales up 46% sequentially last quarter, but management said Europe will remain a slower, more strategic rollout because of pricing pressure and reimbursement hurdles.
